Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 efzofitimod in pulmonary sarcoidosis
NL-OMON60442Phase 3Completed
- Sponsor
- aTyr Pharma
- Start
- Jun 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary sarcoidosis comparing Efzofitimod with Placebo (2 arms). Primary endpoint: Change from baseline in mean daily oral corticosteroid dose at Week 48. Started Jun 2023; status: completed.
02
Drugs
efzofitimod
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on NL-OMON60442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60442.